Lilly does second deal for Adocia's fast insulin

Adocia S.A. (Euronext:ADOC) rose EUR 10.16 (37%) to EUR 37.40 after granting Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to BioChaperone Lispro to treat Type I and Type II diabetes.

Adocia will receive $50 million up front and is eligible for up to $280 million in development and regulatory milestones and up to $240 million in sales milestones, plus tiered royalties. Lilly will reimburse Adocia for certain R&D expenses under the deal, and pay for development and commercialization. ...